Article

Jan Berger, MD, MJ, Discusses the Importance of Medication Adherence

Jan Berger, MD, MJ, president & CEO, Health Intelligence Partners, and editor-in-chief of The American Journal of Pharmacy Benefits, says that historically medication adherence, when it pertained to PBMs, was really just about selling pills-it was an isolated, siloed issue.

Jan Berger, MD, MJ, president & CEO, Health Intelligence Partners, and editor-in-chief of The American Journal of Pharmacy Benefits, says that historically medication adherence, when it pertained to PBMs, was really just about selling pills—it was an isolated, siloed issue. However, pharmacy benefit managers (PBMs) began to recognize that clients were looking at adherence in a bigger, broader sense as they realized how adherence affected their lives, out-of-pocket costs, and workability.

Dr Berger also says that one of the newer areas PBMs are focusing on are medication adherence outcomes.

“Are people take their medications, and if they’re not, what are those barriers that need to be overcome in order to take it?" asks Dr Berger. "So like the rest of healthcare, we are going from a process-oriented world, to an outcomes-oriented world.”

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Videos
Surbhi Sidana, MD, MBBS, Stanford University
Gordon Crofoot, MD, PA
David Awad, PharmD, BCOP
Merrill H. Stewart, MD
Saad Z. Usmani, MD, MBA, FACP, FASCO, Memorial Sloan Kettering Cancer Center
Andrew Evens, DO, MBA, MSc, deputy director for clinical services and chief physician officer, Rutgers Cancer Institute and Jack & Sheryl Morris Cancer Center
Hamlet Gasoyan, PhD
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo